Protalex to Present at The 10^th Annual BIO CEO & Investor Conference

NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB:PRTX) announced today that Steven H. Kane, President and Chief Executive Officer of Protalex, Inc., will give a corporate presentation at The 10^th Annual BIO CEO and Investor Conference being held February 11-13, 2008 at The Waldorf-Astoria in New York City.

Mr. Kane is scheduled to speak on Wednesday, February 13, 2008 at 3:30 PM Eastern Time in the West Foyer. The presentation and additional company information can be accessed on the company’s web site at www.protalex.com.

About Protalex, Inc.

Protalex, Inc. is a biotechnology company engaged in the development of a new class of drugs for the treatment of Rheumatoid Arthritis (RA), Idiopathic Thrombocytopenic Purpura (ITP), and a host of other autoimmune disorders. Additional information about Protalex, Inc. can be found at www.protalex.com.

Cautionary Statement Regarding Forward Looking Information

This release contains forward-looking information about Protalex, Inc. that are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Protalex's future performance, operations and products.

This forward-looking information should be considered only in connection with "Risk Factors" in Protalex's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on July 31, 2007 and its other periodic reports filed with the SEC. Protalex assumes no obligation to update any forward-looking statements or information set forth in this press release.